|
1
|
Li Y, Pan K, Liu LZ, Li YQ, Gu MF, Zhang
H, Shen WX, Xia JC and Li JJ: Sequential cytokine-induced killer
cell immunotherapy enhances the efficacy of the gemcitabine plus
cisplatin chemotherapy regimen for metastatic nasopharyngeal
carcinoma. PLoS One. 10:e01306202015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lee FK, Yip CW, Cheung FC, Leung AK, Chau
RM and Ngan RK: Dosimetric difference amongst 3 techniques:
TomoTherapy, sliding-window intensity-modulated radiotherapy
(IMRT), and RapidArc radiotherapy in the treatment of late-stage
nasopharyngeal carcinoma (NPC). Med Dosim. 39:44–49. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jiang H, Lu H, Yuan H, Huang H, Wei Y,
Zhang Y and Liu X: Dosimetric benefits of placing dose constraints
on the brachial plexus in patients with nasopharyngeal carcinoma
receiving intensity-modulated radiation therapy: A comparative
study. J Radiat Res. 56:114–121. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Peng G, Wang T, Yang KY, Zhang S, Zhang T,
Li Q, Han J and Wu G: A prospective, randomized study comparing
outcomes and toxicities of intensity-modulated radiotherapy vs.
conventional two-dimensional radiotherapy for the treatment of
nasopharyngeal carcinoma. Radiother Oncol. 104:286–293. 2012.
|
|
5
|
Liu N, Cui RX, Sun Y, Guo R, Mao YP, Tang
LL, Jiang W, Liu X, Cheng YK, He QM, et al: A four-miRNA signature
identified from genome-wide serum miRNA profiling predicts survival
in patients with nasopharyngeal carcinoma. Int J Cancer.
134:1359–1368. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lung RW, Wang X, Tong JH, Chau SL, Lau KM,
Cheng SH, Woo JK, Woo J, Leung PC, Ng MH, et al: A single
nucleotide polymorphism in microRNA-146a is associated with the
risk for nasopharyngeal carcinoma. Mol Carcinog. 52 (Suppl
1):E28–E38. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Spence T, Bruce J, Yip KW and Liu FF:
MicroRNAs in nasopharyngeal carcinoma. Chin Clin Oncol. 5:172016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhao L, Lin L, Pan C, Shi M, Liao Y, Bin J
and Liao W: Flotillin-2 promotes nasopharyngeal carcinoma
metastasis and is necessary for the epithelial-mesenchymal
transition induced by transforming growth factor-β. Oncotarget.
6:9781–9793. 2015.PubMed/NCBI
|
|
9
|
Kan R, Shuen WH, Lung HL, Cheung AK, Dai
W, Kwong DL, Ng WT, Lee AW, Yau CC, Ngan RK, et al: NF-κB p65
subunit is modulated by latent transforming growth factor-β binding
protein 2 (LTBP2) in nasopharyngeal carcinoma HONE1 and HK1 cells.
PLoS One. 10:e01272392015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang W, Zeng Z, Fan S, Wang J, Yang J,
Zhou Y, Li X and Huang D: Evaluation of the prognostic value of
TGF-β superfamily type I receptor and TGF-β type II receptor
expression in nasopharyngeal carcinoma using high-throughput tissue
microarrays. J Mol Histol. 43:297–306. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen WJ, Zhang EN, Zhong ZK, Jiang MZ,
Yang XF, Zhou DM and Wang XW: MicroRNA-153 expression and prognosis
in non-small cell lung cancer. Int J Clin Exp Pathol. 8:8671–8675.
2015.PubMed/NCBI
|
|
12
|
Wang W, Feng M, Fan Z, Li J and Lang J:
Clinical outcomes and prognostic factors of 695 nasopharyngeal
carcinoma patients treated with intensity-modulated radiotherapy.
Biomed Res Int. 2014:8149482014.PubMed/NCBI
|
|
13
|
Wang J, Zheng J, Tang T, Zhu F, Yao Y, Xu
J, Wang AZ and Zhang L: A randomized pilot trial comparing position
emission tomography (PET)-guided dose escalation radiotherapy to
conventional radiotherapy in chemoradiotherapy treatment of locally
advanced nasopharyngeal carcinoma. PLoS One. 10:e01240182015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Long GX, Lin JW, Liu DB, Zhou XY, Yuan XL,
Hu GY, Mei Q and Hu GQ: Single-arm, multi-centre phase II study of
lobaplatin combined with docetaxel for recurrent and metastatic
nasopharyngeal carcinoma patients. Oral Oncol. 50:717–720. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bruce JP, Yip K, Bratman SV, Ito E and Liu
FF: Nasopharyngeal cancer: Molecular landscape. J Clin Oncol.
33:3346–3355. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhu LH, Miao XT and Wang NY: Integrated
miRNA-mRNA analysis of Epstein-Barr virus-positive nasopharyngeal
carcinoma. Genet Mol Res. 14:6028–6036. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Low SY, Tan BS, Choo HL, Tiong KH, Khoo AS
and Leong CO: Suppression of BCL-2 synergizes cisplatin sensitivity
in nasopharyngeal carcinoma cells. Cancer Lett. 314:166–175. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pan LL, Wang AY, Huang YQ, Luo Y and Ling
M: Mangiferin induces apoptosis by regulating Bcl-2 and Bax
expression in the CNE2 nasopharyngeal carcinoma cell line. Asian
Pac J Cancer Prev. 15:7065–7068. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li SS, Tang QL, Wang SH, Chen YH, Liu JJ
and Yang XM: Simultaneously targeting Bcl-2 and Akt pathways
reverses resistance of nasopharyngeal carcinoma to TRAIL
synergistically. Tumori. 97:762–770. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Anaya-Ruiz M, Cebada J, Delgado-Lopez G,
Sánchez-Vázquez ML and Pérez-Santos JL: miR-153 silencing induces
apoptosis in the MDA-MB-231 breast cancer cell line. Asian Pac J
Cancer Prev. 14:2983–2986. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lyu X, Fang W, Cai L, Zheng H, Ye Y, Zhang
L, Li J, Peng H, Cho WCS, Wang E, et al: TGFβR2 is a major target
of miR-93 in nasopharyngeal carcinoma aggressiveness. Mol Cancer.
13:512014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Poh YW, Gan SY and Tan EL: Effects of
IL-6, IL-10 and TGF-β on the expression of survivin and apoptosis
in nasopharyngeal carcinoma TW01 cells. Exp Oncol. 34:85–89.
2012.PubMed/NCBI
|
|
23
|
Niu G, Li B, Sun L and An C: MicroRNA-153
inhibits osteosarcoma cells proliferation and invasion by targeting
TGF-β2. PLoS One. 10:e01192252015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liang C, Li X, Zhang L, Cui D, Quan X and
Yang W: The anti-fibrotic effects of microRNA-153 by targeting
TGFBR-2 in pulmonary fibrosis. Exp Mol Pathol. 99:279–285. 2015.
View Article : Google Scholar : PubMed/NCBI
|
